Jubilant Pharmova Reports Q1'FY27 Results; Revenue Grows 17% Amid Operational Challenges
Jubilant Pharmova Limited announced its financial and operational performance for the quarter ended June 30, 2026. The company reported a consolidated revenue of Rs. 2,229 Cr., marking 17% growth year-on-year (YoY). Total Income stood at Rs. 2,249 Cr., reflecting an 18% YoY increase. However, EBITDA decreased by 11% compared to the same period last year.The company’s board meeting approved the financial results for Q1'FY27. While revenue exhibited solid growth across all business segments, profitability metrics saw pressure. Reported PAT for the quarter was Rs. 56 Cr., a 45% decrease YoY from Rs. 103 Cr. in Q1'FY26.
Segmental Performance Snapshot
The results highlighted varied performances across Jubilant Pharmova’s business units, driven by strong growth in some areas and operational challenges in others.
| Business Segment | Revenue (Rs. Cr.) | EBITDA (Rs. Cr.) | Margin (%) | Key Commentary |
|---|---|---|---|---|
| Radiopharma | 322 | 110 | 34% | Commercial batch production started for SPECT products at CMO Montreal; expected to be released in Q2'FY27. |
| Radiopharmacy | 700 | 12 | 2% | Strategic investment of US$ 60+ million underway to expand PET manufacturing network from 3 to 9 sites, operational by FY28. |
| Allergy Immunotherapy | 214 | 66 | 31% | Revenue grew across US and outside US markets; margins reduced YoY due to lower production. |
| CDMO Sterile Injectables (Total) | 496 | 45 | 9% | Line 3 technology transfer revenues are increasing at Spokane facility. |
| CRDMO Drug Discovery Services | 174 | 45 | 26% | Anticipates competitive intensity increase in the large-pharma segment, while biotech demand conditions improve. |
| CDMO API | 135 | 19 | - | Revenue and EBITDA margins decreased due to industry wide pricing pressure and raw material cost increases linked to the Middle East conflict. |
| Generics | 173 | 4 | 2% | Launched two new products in Q1'FY27, with an outlook for improved profitability. |
Operational Highlights Across Key Verticals
CDMO Sterile Injectables: The business segment reported a 34% revenue growth to Rs. 496 Cr. from incremental revenues derived from Line 3 at the Spokane facility. These technology transfer programs involve over 10 products across multiple formats, and one of the world's largest oncology products has been onboarded for Line 3. Commercial batch production is expected to commence in late FY27, pending FDA approval.
Radiopharmaceuticals: Revenue grew by 19% YoY to Rs. 322 Cr., with EBITDA at Rs. 110 Cr. The company noted that margins declined due to the unavailability of certain high-margin SPECT radiopharmaceutical products. Post successful media fills, commercial batch production has begun at CMO Montreal, and these batches are anticipated for release in Q2'FY27, leading to an expected normalization of revenue and EBITDA from H2'FY27 onwards.
Allergy Immunotherapy: The business saw a 18% growth in revenue, reaching Rs. 214 Cr., driven by strong performance in both US and outside US markets.
Drug Discovery Services (CRDMO): Revenues grew by 8%, with EBITDA increasing by 43%. The company remains bullish on the mid to long-term prospects of the Indian CRO industry due to talent availability and preference for 'friendshoring' related to the Biosecure Act, aiming to scale up capacity to 4,000 FTEs by FY30.
Generics: Revenues grew marginally at 4% to Rs. 173 Cr., following the launch of two new products in Q1'FY27.
The company continues to invest significantly into its future growth pipeline across various segments. For instance, the Radiopharmacy network is expanding its PET manufacturing capability from three sites to nine by FY28, supported by a proposed investment of US$ 60+ million.
Looking ahead, Jubilant Pharmova projects that EBITDA margins are expected to strengthen in H2'FY27 as production stabilizes at the CMO Montreal facility. The company aims to double revenues and increase profitability across its various segments toward its Vision 2030 targets.
JUBLPHARMA Stock Price Movement
Jubilant Pharmova Limited shares closed strongly today in post-market trading after rising 3.00%, settling at ₹962.70. The equity saw a traded volume of 357,574 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: